论文部分内容阅读
本实验采用ELISA夹心法对49例原发性肝癌患者血清中可溶性白细胞介素Ⅱ受体进行了检测，8例为治愈患者；12例伴有转移；29例无转移，以21例健康献血人员为对照，结果显示原发性肝癌患者血清sIL—2R水平显著升高，伴有转移组明显高于其它组，治愈组同正常对照组仍相差明显，结果表明，sIL－2R异常升高在原发性肝癌患者机体免疫抑制机制及免疫监视能力下降方面起着极重要的作用，且和肿瘤转移及病情变化密切相关；提示sIL－2R可作为原发性肝癌患者辅助诊断及病情监测疗效观察指标。
In this study, soluble interleukin-II receptors in serum of 49 patients with primary liver cancer were detected by ELISA method. Eight patients were cured patients; 12 patients were associated with metastases; 29 patients had no metastases, 21 healthy blood donors As a control, the results showed that serum sIL-2R levels in patients with primary liver cancer were significantly higher, with the metastasis group was significantly higher than other groups, the cure group was still significantly different from the normal control group, the results showed that sIL-2R abnormal increase in the original The immunosuppressive mechanism and the decline of immune surveillance ability in patients with hepatocellular carcinoma play a very important role, and it is closely related to tumor metastasis and disease changes. It is suggested that sIL-2R can be used as an indicator for the diagnosis and monitoring of the disease in primary liver cancer patients. .